The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients

[1]  M. Jankowski,et al.  Influence of NSAID Use Among Colorectal Cancer Survivors on Cancer Outcomes , 2017, American journal of clinical oncology.

[2]  P. Catalano,et al.  Point-of-care clinical decision support for cancer symptom management: Results of a group randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Mulshine,et al.  Issues with implementing a high‐quality lung cancer screening program , 2014, CA: a cancer journal for clinicians.

[4]  P. Bunn,et al.  Recent clinical advances in lung cancer management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  V. Zdravkovic,et al.  The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer , 2014, Medical Oncology.

[6]  Yibo Gao,et al.  Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[7]  Y. Nakanishi,et al.  Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. , 2013, Lung cancer.

[8]  Yongjung Park,et al.  Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. , 2013, Lung cancer.

[9]  H. Lee,et al.  Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer , 2012, BMC Cancer.

[10]  B. Cho,et al.  Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2012, Yonsei medical journal.

[11]  J. Sørensen,et al.  Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. , 2012, Lung cancer.

[12]  M. Edelman,et al.  CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304 , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Sarah Park,et al.  The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer , 2012, Tumor Biology.

[14]  Bo Wang,et al.  Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis , 2011, Cancer biology & therapy.

[15]  Pauline M Rudd,et al.  Novel glycan biomarkers for the detection of lung cancer. , 2011, Journal of proteome research.

[16]  F. Angiero,et al.  Amyloid deposition in the tongue: clinical and histopathological profile. , 2010, Anticancer research.

[17]  Tetsuya Shimizu,et al.  Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. , 2010, Anticancer research.

[18]  A. Gemma,et al.  F1000 highlights , 2010 .

[19]  Ping Chen,et al.  Survival and prognostic factors in small cell lung cancer , 2010, Medical oncology.

[20]  Irina Kusmartseva,et al.  Panel of serum biomarkers for the diagnosis of lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  W. Hsu,et al.  Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. , 2007, The Annals of thoracic surgery.

[23]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[24]  N. Kiviat,et al.  Molecular Biomarkers for Cancer Detection in Blood and Bodily Fluids , 2006, Critical reviews in clinical laboratory sciences.

[25]  N. Viñolas,et al.  Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. , 2005, Anticancer research.

[26]  F. Barlesi,et al.  CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy , 2004, British Journal of Cancer.

[27]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[28]  P. Wang,et al.  The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer. , 2013, Cancer biomarkers : section A of Disease markers.

[29]  M. Kosacka,et al.  Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. , 2009, Polskie Archiwum Medycyny Wewnetrznej.

[30]  L. Tanoue,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumors , 2009 .

[31]  B. Thirion,et al.  CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. , 1994, European journal of cancer.

[32]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.